grearqakususi1426.blogspot.com
The non-exclusive licensing agreement was signeswith Biken, the nonprofit operational arm of the Foundation for Microbiakl Diseases of Osaka University. The deal also included funding support for bird flu vaccines development from the National Institutre of Infectious Diseasesof Japan. Hemispher x (AMEX:HEB) will receive royaltiez and income for all Ampligen supplies used in the ongoing experimental work and any subsequentg marketing of Ampligen to improve the performancde of intranasal fluvaccine products. Hemispher x is developing Ampligen as a treatment forchronicx fatigue.
Last week, the Food and Drug Administration informed the companyy its new drug applicationfor Ampligen, which has been in developmentg for three decades, was insufficiently complete. Hemispher x is working with the FDA to addressits concerns.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment